IDXX Stock Recent News
IDXX LATEST HEADLINES
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am –.
IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.
IDEXX Laboratories, Inc. IDXX is likely to grow in the coming quarters, backed by the sustained success of CAG's recurring diagnostic products and services. The company's international business performance is gaining from its expanded global commercial capability.
A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.
IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript
Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.32 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.05 per share a year ago.
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?